The Latest Breaking News from Eli Lilly

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

The healthcare industry is set for growth due to the growing demand for quality treatments and ongoing progress in medical technology. Hence, investors might consider investing in healthcare stocks, Eli Lilly (LLY), Thermo Fisher Scientific (TMO), and Abbott Laboratories (ABT) for a healthy portfolio in 2025. Read more….

Discover two telehealth stocks, Hims & Hers (HIMS) and Teladoc (TDOC), poised to benefit from Trump's FDA nominee, Dr. Marty Makary, a telemedicine advocate.

Mounjaro to be rolled out to only patients with the highest needs, the NHS has said

The decision will help ‘protect other vital NHS services’.

In the first head-to-head test, people using Eli Lilly’s Zepbound lost just over 50 pounds while those using competitor Novo Nordisk’s Wegovy shed more than 33 pounds

Shares of Eli Lilly (LLY) are approaching a price level that had previously been a peak. There is a good chance they hit resistance at it.

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly (NYSE:LLY).

Eli Lilly has outperformed the S&P 500 over the past year, and analysts are highly optimistic about the stock’s prospects.